YKL-5-124 manufacturers
- YKL-5-124
-
- $97.00 / 1mg
-
2025-04-27
- CAS:1957203-01-8
- Min. Order:
- Purity: 99.5%
- Supply Ability: 10g
|
| | YKL-5-124 Basic information |
| Product Name: | YKL-5-124 | | Synonyms: | YKL-5-124;Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-[(1S)-2-(dimethylamino)-1-phenylethyl]-4,6-dihydro-6,6-dimethyl-3-[[4-[(1-oxo-2-propen-1-yl)amino]benzoyl]amino]-;(S)-3-(4-Acrylamidobenzamido)-N-(2-(dimethylamino)-1-phenylethyl)-6,6-dimethyl-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide;T-loop,phosphorylation,inhibit,arrest,CDK7,Inhibitor,CDK,YKL5124,YKL 5 124,CDK7/Mat1/CycH,Cyclin dependent kinase,cell-cycle,transcription,Pol-II,irreversible,covalent;YKL-5-124, 10 mM in DMSO | | CAS: | 1957203-01-8 | | MF: | C28H33N7O3 | | MW: | 515.61 | | EINECS: | | | Product Categories: | | | Mol File: | 1957203-01-8.mol |  |
| | YKL-5-124 Chemical Properties |
| Boiling point | 706.1±60.0 °C(Predicted) | | density | 1.284±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO : 250 mg/mL (484.86 mM; Need ultrasonic) | | pka | 12.78±0.40(Predicted) | | form | Solid | | color | White to off-white |
| | YKL-5-124 Usage And Synthesis |
| Uses | YKL-5-124 is a potent, selective, irreversible and covalent CDK7 inhibitor with IC50s of 53.5 nM and 9.7 nM for CDK7 and CDK7/Mat1/CycH, respectively. YKL-5-124 is >100-fold greater selective for CDK7 than CDK9 and CDK2, and inactive against CDK12 and CDK13. YKL-5-124 induces a strong cell-cycle arrest, inhibits E2F-driven gene expression, and exhibits little effect on RNA polymerase II phosphorylation status[1]. | | Biological Activity | YKL-5-124 is a potent, selective, irreversible and covalent CDK7 inhibitor with IC50s of 53.5 nM and 9.7 nM for CDK7 and CDK7/Mat1/CycH, respectively. YKL-5-124 is >100-fold greater selective for CDK7 than CDK9 and CDK2, and inactive against CDK12 and CDK13. YKL-5-124 induces a strong cell-cycle arrest, inhibits E2F-driven gene expression, and exhibits little effect on RNA polymerase II phosphorylation status[1].
YKL-5-124 (0-2000 nM; 72 hours; HAP1 cells) treatment causes a dose-dependent increase in G1- and G2/M-phase cells and a corresponding loss of S-phase cells[1].YKL-5-124 (0-2000 nM; 24 hours; HAP1 WT cells) treatment inhibits CDK1 T-loop phosphorylation, and to a lesser extent CDK2 T-loop phosphorylation in a concentration-dependent fashion[1].Treatment of cells with YKL-5-124 as a competitor at a concentration of about 30 nM blocks pull-down of CDK7-cyclin H but has no effect on the pull-down of cyclin K-CDK12/13 in HAP1 cells. Treatment with 100 nM YKL-5-124 reduces CDK7-cyclin H binding to bioTHZ1 by >50% at 30 min[1]. | | IC 50 | CDK7: 53.5 nM (IC50); CDK7/Mat1/CycH: 9.7 nM (IC50); CDK2: 1300 nM (IC50); CDK9: 3020 nM (IC50) | | storage | Store at -20°C | | References | [1]. Olson CM, et al. Development of a Selective CDK7 Covalent Inhibitor Reveals Predominant Cell-Cycle Phenotype. Cell Chem Biol. 2019 Jun 20;26(6):792-803.e10. |
| | YKL-5-124 Preparation Products And Raw materials |
|